Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Irritable Bowel Syndrome

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 87 articles:
HTML format



Single Articles


    December 2022
  1. FITZPATRICK JA, Halmos EP
    Editorial: gluten-free but not pain-free in IBS.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    


  2. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Editorial: gluten-free but not pain-free in IBS-authors' reply.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    


    November 2022
  3. QUIGLEY EMM, Markinson L, Stevenson A, Treasure FP, et al
    Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Nov 11. doi: 10.1111/apt.17310.
    PubMed     Abstract available


  4. LEMBO A, Kuo B, Boinpally R, Li E, et al
    Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2022 Nov 2. doi: 10.1111/apt.17274.
    PubMed     Abstract available


  5. QUIGLEY EMM
    Editorial: 5-aminosalicylic acid fails to impact on irritable bowel syndrome-wrong population, intervention, target or hypothesis?
    Aliment Pharmacol Ther. 2022;56:1497-1498.
    PubMed    


    October 2022
  6. GU Y, Xiang Y
    Letter: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:1215-1216.
    PubMed    


  7. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1217-1218.
    PubMed    


  8. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed    


  9. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed    


    September 2022
  10. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Sep 29. doi: 10.1111/apt.17239.
    PubMed     Abstract available


  11. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:894-895.
    PubMed    


  12. SHAH ED, Wechsler EV
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:892-893.
    PubMed    


    August 2022
  13. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    PubMed     Abstract available


  14. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Aug 9. doi: 10.1111/apt.17179.
    PubMed     Abstract available


  15. CASTRO TEJERA V, Ohman L, Aabakken L, Fellstrom B, et al
    Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-Effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
    Aliment Pharmacol Ther. 2022 Aug 8. doi: 10.1111/apt.17182.
    PubMed     Abstract available


    July 2022
  16. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17132.
    PubMed     Abstract available


  17. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:160-161.
    PubMed    


  18. MIKOCKA-WALUS A, Lores T
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:158-159.
    PubMed    


  19. BIESIEKIERSKI JR, Wu J, Van Oudenhove L
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:368-369.
    PubMed    


  20. HALMOS EP, Gibson PR
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs.
    Aliment Pharmacol Ther. 2022;56:366-367.
    PubMed    


  21. BIESIEKIERSKI JR, Manning LP, Murray HB, Vlaeyen JWS, et al
    Review article: Exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jul 1. doi: 10.1111/apt.17111.
    PubMed     Abstract available


    June 2022
  22. COFFIN PB, Duboc H
    Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jun 2. doi: 10.1111/apt.17064.
    PubMed     Abstract available


  23. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1590-1591.
    PubMed    


  24. BERINSTEIN JA, Fendrick AM
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition.
    Aliment Pharmacol Ther. 2022;55:1588-1589.
    PubMed    


    May 2022
  25. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16934.
    PubMed     Abstract available


  26. QUIGLEY EMM
    Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
    Aliment Pharmacol Ther. 2022;55:1218-1219.
    PubMed    


  27. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
    Aliment Pharmacol Ther. 2022 May 1. doi: 10.1111/apt.16939.
    PubMed     Abstract available


    April 2022
  28. FOX M
    Editorial: meal-induced symptoms in irritable bowel syndrome-"all in the mind"?
    Aliment Pharmacol Ther. 2022;55:880-881.
    PubMed    


    February 2022
  29. WU J, Masuy I, Biesiekierski JR, Fitzke HE, et al
    Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16812.
    PubMed     Abstract available


  30. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16816.
    PubMed     Abstract available


    December 2021
  31. LIU JJ, Brenner DM
    Review article: current and future treatment approaches for IBS with constipation.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S53-S62.
    PubMed     Abstract available


  32. SHIHA MG, Aziz I
    Review article: Physical and psychological comorbidities associated with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S12-S23.
    PubMed     Abstract available


  33. YADAV YS, Eslick GD, Talley NJ
    Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S24-S32.
    PubMed     Abstract available


  34. NEE J, Lembo A
    Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S63-S74.
    PubMed     Abstract available


  35. BLACK CJ
    Review article: Diagnosis and investigation of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S33-S43.
    PubMed     Abstract available


  36. RUDDY J
    Review article: the patients' experience with irritable bowel syndrome and their search for education and support.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S44-S52.
    PubMed     Abstract available


  37. SPERBER AD
    Review article: epidemiology of IBS and other bowel disorders of gut-brain interaction (DGBI).
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S1-S11.
    PubMed     Abstract available


  38. PAINE P
    Review article: current and future treatment approaches for pain in IBS.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S75-S88.
    PubMed     Abstract available


    November 2021
  39. GROVER M, Berumen A, Peters S, Wei T, et al
    Editorial: understanding IBS pathophysiology through "converging channels" of research-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1215-1216.
    PubMed    


  40. ELWING JE, Sayuk GS
    Editorial: understanding IBS pathophysiology through "converging channels" of research.
    Aliment Pharmacol Ther. 2021;54:1213-1214.
    PubMed    


    October 2021
  41. DELLSCHAFT N, Hoad C, Marciani L, Gowland P, et al
    Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies.
    Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16673.
    PubMed     Abstract available


  42. MCNAUGHTON DT, Andreasson A, Ljotsson B, Beath AP, et al
    Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life.
    Aliment Pharmacol Ther. 2021 Oct 19. doi: 10.1111/apt.16651.
    PubMed     Abstract available


  43. ZAND IRANI M, Jones MP, Halland M, Herrick L, et al
    Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16630.
    PubMed     Abstract available


    September 2021
  44. GILLAN C
    Review article: the effectiveness of group and self-help hypnotherapy for irritable bowel syndrome and the implications for improving patients' choice and access to treatment.
    Aliment Pharmacol Ther. 2021 Sep 30. doi: 10.1111/apt.16623.
    PubMed     Abstract available


  45. GROVER M, Berumen A, Peters S, Wei T, et al
    Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16591.
    PubMed     Abstract available


    August 2021
  46. AKBANI U, Vasant DH
    Editorial: important insights into prescribing practices and training needs of gastroenterologists regarding use of central neuromodulators in IBS.
    Aliment Pharmacol Ther. 2021;54:339-340.
    PubMed    


    July 2021
  47. KOLOSKI NA, Jones M, Walker MM, Keely S, et al
    Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress: a population-based study of 1322 Australians.
    Aliment Pharmacol Ther. 2021 Jul 11. doi: 10.1111/apt.16500.
    PubMed     Abstract available


  48. NELSON AD, Black CJ, Houghton LA, Lugo-Fagundo NS, et al
    Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:198-199.
    PubMed    


  49. TALLEY NJ, Walker MM, Agreus L, Andreasson A, et al
    Editorial: tobacco use in functional dyspepsia-another smoking gun? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:79.
    PubMed    


  50. WOO MMK, Andrews CN
    Editorial: tobacco use in functional dyspepsia-another smoking gun?
    Aliment Pharmacol Ther. 2021;54:78.
    PubMed    


  51. VASANT DH
    Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating-a step in the right direction for targeted treatment?
    Aliment Pharmacol Ther. 2021;54:196-197.
    PubMed    


    June 2021
  52. NULSEN B, LeBrett W, Drossman DA, Chang L, et al
    A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16467.
    PubMed     Abstract available


  53. NELSON AD, Black CJ, Houghton LA, Lugo-Fagundo NS, et al
    Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16437.
    PubMed     Abstract available


    May 2021
  54. TALLEY NJ, Powell N, Walker MM, Jones MP, et al
    Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population-based studies.
    Aliment Pharmacol Ther. 2021 May 13. doi: 10.1111/apt.16372.
    PubMed     Abstract available


  55. SIMONS M, Taft TH
    Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management.
    Aliment Pharmacol Ther. 2021;53:1151-1152.
    PubMed    


  56. BLACK CJ, Ford AC
    Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1153-1154.
    PubMed    


    March 2021
  57. BLACK CJ, Yiannakou Y, Guthrie E, West R, et al
    Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16322.
    PubMed     Abstract available


  58. HALMOS EP
    Editorial: defining a microbial signature to predict non-response to a FODMAP diet-a step closer or is it?
    Aliment Pharmacol Ther. 2021;53:646-647.
    PubMed    


  59. CHUMPITAZI BP, Shulman RJ
    Editorial: defining a microbial signature to predict non-response to a low FODMAP diet-a step closer or is it? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:648-649.
    PubMed    


    December 2020
  60. CHUMPITAZI BP, Hoffman KL, Smith DP, McMeans AR, et al
    Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures.
    Aliment Pharmacol Ther. 2020 Dec 13. doi: 10.1111/apt.16204.
    PubMed     Abstract available


  61. PERTTU L, Jonna J, Anna H, Eero M, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required? Authors' reply.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


  62. EL-SALHY M, Hausken T, Gunnar Hatlebakk J
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required?
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    October 2020
  63. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1239-1240.
    PubMed    


  64. BOSMAN MHMA, Keszthelyi D
    Letter: placebo run-in for IBS clinical trials-is it useful?
    Aliment Pharmacol Ther. 2020;52:1237-1238.
    PubMed    


    September 2020
  65. IANIRO G, Porcari S, Ford AC, Gasbarrini A, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement.
    Aliment Pharmacol Ther. 2020;52:923-924.
    PubMed    


  66. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:925-926.
    PubMed    


    August 2020
  67. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:557-558.
    PubMed    


  68. XU E, Vilella RC, Segal JP, Mullish BH, et al
    Letter: faecal microbiota transplantation for IBS.
    Aliment Pharmacol Ther. 2020;52:556-557.
    PubMed     Abstract available


  69. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;52:715-716.
    PubMed    


  70. BLACK CJ, Barberio B, Ford AC
    Editorial: minesapride for irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2020;52:713-714.
    PubMed    


    June 2020
  71. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
    Aliment Pharmacol Ther. 2020 Jun 25. doi: 10.1111/apt.15907.
    PubMed     Abstract available


  72. GIBSON PR, Halmos EP, Muir JG
    Review article: FODMAPS, prebiotics and gut health. The FODMAP hypothesis revisited.
    Aliment Pharmacol Ther. 2020 Jun 20. doi: 10.1111/apt.15818.
    PubMed     Abstract available


  73. OSTOJIC SM
    Letter: balancing gut hydrogen as a proxy for bacteriotherapy benefits in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:1451-1452.
    PubMed    


    May 2020
  74. RAO SSC, Xiang X, Yan Y, Rattanakovit K, et al
    Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
    Aliment Pharmacol Ther. 2020 May 13. doi: 10.1111/apt.15772.
    PubMed     Abstract available


  75. BASILISCO G, Barbara G, Bellini M, Cataudella G, et al
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;51:910-911.
    PubMed    


  76. BALLOU S, Lembo A
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation.
    Aliment Pharmacol Ther. 2020;51:909-910.
    PubMed    


    April 2020
  77. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15740.
    PubMed     Abstract available


    February 2020
  78. BASILISCO G
    Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15657.
    PubMed     Abstract available


    January 2020
  79. REJ A, Buckle RL, Shaw CC, Trott N, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:184-185.
    PubMed    


  80. TUCK C, Vanner S, Camilleri M, Jing Wang X, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:185-186.
    PubMed    


  81. FORD AC
    Commentary: estimating the prevalence of IBS globally-past, present and future.
    Aliment Pharmacol Ther. 2020;51:198-199.
    PubMed    


  82. VAKIL N
    Commentary: tegaserod and IBS, two decades on.
    Aliment Pharmacol Ther. 2020;51:200-201.
    PubMed    


    May 2019
  83. FORD AC, Harris LA, Lacy BE, Quigley EMM, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1254-1255.
    PubMed    


  84. SUN P, Zhang W, Miao Y, Chen Z, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS.
    Aliment Pharmacol Ther. 2019;49:1253-1254.
    PubMed    


    April 2019
  85. MITCHELL H, Porter J, Gibson PR, Barrett J, et al
    Letters: low FODMAP diet-directions for future research and the low FODMAP diet is not the only diet for IBS-authors' reply.
    Aliment Pharmacol Ther. 2019;49:1109-1110.
    PubMed    


  86. O'BRIEN L, Brown S, Gearry RB, Day AS, et al
    Letter: low FODMAP diet-directions for future research.
    Aliment Pharmacol Ther. 2019;49:1107-1108.
    PubMed    


  87. REJ A, Trott N, Sanders DS, Aziz I, et al
    Letter: the low FODMAP diet is not the only diet for IBS.
    Aliment Pharmacol Ther. 2019;49:1108-1109.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: